640 related articles for article (PubMed ID: 34729299)
1. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
2. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
Banerjee S; Roy S
Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
[TBL] [Abstract][Full Text] [Related]
3. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
4. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
Ma H; Kang Z; Foo TK; Shen Z; Xia B
Hepatology; 2023 Jan; 77(1):33-47. PubMed ID: 35006619
[TBL] [Abstract][Full Text] [Related]
5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
7. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
Front Oncol; 2021; 11():742833. PubMed ID: 35087742
[TBL] [Abstract][Full Text] [Related]
8. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
9. DNA repair mechanisms in dividing and non-dividing cells.
Iyama T; Wilson DM
DNA Repair (Amst); 2013 Aug; 12(8):620-36. PubMed ID: 23684800
[TBL] [Abstract][Full Text] [Related]
10. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
11.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
12. The interplay between DNA repair and autophagy in cancer therapy.
Zhang D; Tang B; Xie X; Xiao YF; Yang SM; Zhang JW
Cancer Biol Ther; 2015; 16(7):1005-13. PubMed ID: 25985143
[TBL] [Abstract][Full Text] [Related]
13. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
14. Alterations of DNA damage repair in cancer: from mechanisms to applications.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Ann Transl Med; 2020 Dec; 8(24):1685. PubMed ID: 33490197
[TBL] [Abstract][Full Text] [Related]
15. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
16. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
[TBL] [Abstract][Full Text] [Related]
17. When DNA-damage responses meet innate and adaptive immunity.
Tong J; Song J; Zhang W; Zhai J; Guan Q; Wang H; Liu G; Zheng C
Cell Mol Life Sci; 2024 Apr; 81(1):185. PubMed ID: 38630271
[TBL] [Abstract][Full Text] [Related]
18. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
19. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
20. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
Rosen DB; Leung LY; Louie B; Cordeiro JA; Conroy A; Shapira I; Fields SZ; Cesano A; Hawtin RE
J Transl Med; 2014 Jun; 12():184. PubMed ID: 24965603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
